乳腺癌患者心碎综合征的治疗：曲妥珠单抗与心力衰竭
The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.
作者信息
Walker Jonathan R, Singal Pawan K, Jassal Davinder S
机构信息
Institute of Cardiovascular Sciences, St Boniface General Hospital Research Centre;
出版信息
Exp Clin Cardiol. 2009 Fall;14(3):e62-7.
Abstract
Breast cancer, a leading cause of increased morbidity and mortality among women, overexpresses the human epidermal growth factor receptor 2 in approximately 20% to 30% of cases. Trastuzumab (Trz), a monoclonal antibody against the human epidermal growth factor receptor 2, improves survival in breast cancer patients in both the adjuvant and metastatic settings. Despite the therapeutic benefits of Trz, there is an increased incidence of cardiotoxicity, particularly when administered following anthracycline-based chemotherapy. The pathogenesis underlying Trz-mediated cardiotoxicity remains poorly understood. The present review focuses on the current understanding of Trz-mediated cardiotoxicity from both the basic and clinical science perspectives.
摘要
乳腺癌是女性发病率和死亡率上升的主要原因之一，在约20%至30%的病例中过度表达人表皮生长因子受体2。曲妥珠单抗（Trz）是一种针对人表皮生长因子受体2的单克隆抗体，在辅助治疗和转移性治疗中均可提高乳腺癌患者的生存率。尽管Trz具有治疗益处，但心脏毒性的发生率有所增加，尤其是在基于蒽环类化疗后使用时。Trz介导的心脏毒性的发病机制仍知之甚少。本综述从基础科学和临床科学的角度聚焦于对Trz介导的心脏毒性的当前认识。
相似文献
1
The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure.
Exp Clin Cardiol. 2009 Fall;14(3):e62-7.
2
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.
Exp Clin Cardiol. 2011 Fall;16(3):70-4.
3
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
Eur J Cancer. 2019 Oct;120:1-9. doi: 10.1016/j.ejca.2019.07.015. Epub 2019 Aug 21.
4
The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
Cardiovasc Ultrasound. 2015 Apr 3;13:18. doi: 10.1186/s12947-015-0011-x.
5
Doxorubicin and trastuzumab regimen induces biventricular failure in mice.
J Am Soc Echocardiogr. 2014 May;27(5):568-79. doi: 10.1016/j.echo.2014.01.014. Epub 2014 Feb 15.
6
Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Indian J Pharmacol. 2016 Sep-Oct;48(5):490-497. doi: 10.4103/0253-7613.190719.
7
The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity.
J Am Soc Echocardiogr. 2011 Jun;24(6):699-705. doi: 10.1016/j.echo.2011.01.018. Epub 2011 Feb 24.
8
Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab.
Front Physiol. 2021 Apr 7;12:658790. doi: 10.3389/fphys.2021.658790. eCollection 2021.
9
Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
Can J Physiol Pharmacol. 2014 Jul;92(7):546-50. doi: 10.1139/cjpp-2013-0470. Epub 2014 Jan 31.
10
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
N Engl J Med. 2001 Mar 15;344(11):783-92. doi: 10.1056/NEJM200103153441101.
引用本文的文献
1
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
BMC Cancer. 2017 Nov 7;17(1):722. doi: 10.1186/s12885-017-3712-8.
2
Risk factors for anthracycline-associated cardiotoxicity.
Support Care Cancer. 2016 May;24(5):2173-2180. doi: 10.1007/s00520-015-3008-y. Epub 2015 Nov 12.
3
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.
Exp Clin Cardiol. 2011 Fall;16(3):70-4.
本文引用的文献
1
Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?
Target Oncol. 2009 Apr;4(2):77-88. doi: 10.1007/s11523-009-0112-2. Epub 2009 May 6.
2
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.
J Clin Oncol. 2009 Jun 1;27(16):2638-44. doi: 10.1200/JCO.2008.17.9549. Epub 2009 Apr 6.
3
Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy.
J Am Soc Echocardiogr. 2009 Apr;22(4):418-24. doi: 10.1016/j.echo.2009.01.016. Epub 2009 Mar 9.
4
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring.
Br J Cancer. 2009 Mar 10;100(5):684-92. doi: 10.1038/sj.bjc.6604909.
5
Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin).
Rev Port Cardiol. 2008 Oct;27(10):1277-96.
6
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Breast Cancer Res Treat. 2009 Oct;117(3):591-8. doi: 10.1007/s10549-008-0306-9. Epub 2009 Jan 21.
7
Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study.
Breast Cancer Res Treat. 2009 Sep;117(2):357-64. doi: 10.1007/s10549-008-0260-6. Epub 2008 Dec 10.
8
Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways.
J Biol Chem. 2009 Jan 23;284(4):2080-7. doi: 10.1074/jbc.M804570200. Epub 2008 Nov 18.
9
Cancer in Canada in 2008.
CMAJ. 2008 Nov 18;179(11):1163-70. doi: 10.1503/cmaj.080760.
10
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Clin Breast Cancer. 2008 Oct;8(5):453-6. doi: 10.3816/CBC.2008.n.056.
Zotero 插件